Rigel Pharmaceuticals Enters Collaboration and License Agreement with Grifols, S.A. to Commercialize Fostamatinib in Europe

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/8/2026

1. SPY
2. USO
3. IONQ
4. IONS
5. QCOM
6. ACN
7. AZN
8. ROIV
9. AAPL
10. HOOD

Go back to Rigel Pharmaceuticals Enters Collaboration and License Agreement with Grifols, S.A. to Commercialize Fostamatinib in Europe
Grifols Sa Barcelona Sponsored ADR (AMEX: GIKLY) Delayed: 5.75 --0 (-0%)
Previous Close $5.75    52 Week High $24.05 
Open $5.75    52 Week Low $9.74 
Day High $5.75    P/E N/A 
Day Low $5.75    EPS $0.00 
Volume 34,273,561       

EAGLE CAPITAL GROWTH FUND, Inc. (NYSE: GRF) Delayed: 10.43 +0.21 (2.05%)
Previous Close $10.22    52 Week High $21.75 
Open $10.43    52 Week Low $6.41 
Day High $10.43    P/E N/A 
Day Low $10.43    EPS $0.00 
Volume 193       

GRIFOLS SP ADR-B (NASDAQ: GRFS) Delayed: 7.75 -0.05 (0.64%)
Previous Close $7.80    52 Week High $35.35 
Open $7.78    52 Week Low $14.07 
Day High $7.83    P/E N/A 
Day Low $7.74    EPS $0.00 
Volume 298,389       

Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) Delayed: 47.37 -1.3 (2.67%)
Previous Close $48.67    52 Week High $4.38 
Open $48.09    52 Week Low $1.88 
Day High $48.11    P/E N/A 
Day Low $46.61    EPS $-1.12 
Volume 248,396